Recaticimab

Recaticimab is a novel monoclonal antibody that targets specific immune pathways to modulate immune responses. Its primary mechanism involves altering immune cell activity, which may have implications for treating autoimmune conditions and enhancing immune resilience. This compound is relevant for longevity and health optimization as it could potentially reduce chronic inflammation and improve immune system function.